@article{23d5d42a66084a8dadc4890ce88edf2b,
title = "Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis",
keywords = "arthritis, biological therapy, epidemiology, methotrexate, rheumatoid",
author = "Satoshi Takanashi and Yuko Kaneko and Tsutomu Takeuchi",
note = "Funding Information: Competing interests YK has received grants or speaking fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi and UCB. TT has received research grants or speaking fees from Astellas Pharma, Bristol–Myers KK, Chugai Pharmaceutical Co, Daiichi Sankyo Co, Takeda Pharmaceutical Co, Teijin Pharma, AbbVie GK, Asahikasei Pharma Corp, Mitsubishi Tanabe Pharma, Astra Zeneca KK, Eli Lilly Japan KK, Novartis Pharma KK, Abbivie GK, Nipponkayaku Co, Janssen, Pharmaceutical KK, Taiho Pharmaceutical Co and Pfizer Japan.",
year = "2021",
month = nov,
day = "1",
doi = "10.1136/annrheumdis-2021-220315",
language = "English",
volume = "80",
pages = "1491--1493",
journal = "Annals of the rheumatic diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "11",
}